BAY 60-2770 | 1027642-43-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: BAY 60-2770
• 英文别名: 4-({(4-carboxybutyl)[2-(5-fluoro-2-{[4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]amino}methyl) benzoic acid；4-({(4-Carboxybutyl)[2-(5-Fluoro-2-{[4'-(Trifluoromethyl)biphenyl-4-Yl]methoxy}phenyl)ethyl]amino}methyl)benzoic Acid；4-[[4-carboxybutyl-[2-[5-fluoro-2-[[4-[4-(trifluoromethyl)phenyl]phenyl]methoxy]phenyl]ethyl]amino]methyl]benzoic acid
• CAS: 1027642-43-8
• 化学式: C₃₅H₃₃F₄NO₅
• 分子量: 623.644
• InChiKey: CRQMDXFUKDWARU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  45
• 可旋转键数：
  15
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  87.1
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  4-{[(2-{5-fluoro-2-[(4'-trifluoromethyl-1,1'-biphenyl-4-yl)methoxy]phenyl}ethyl)(5-methoxy-5-oxopentyl)amino]methyl}benzoic acid methyl ester 在 甲醇 、 sodium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 以57.3%的产率得到BAY 60-2770
  参考文献：
  名称：

  NEUARTIGE AMINODICARBONSÄUREDERIVATE MIT PHARMAZEUTISCHEN EIGENSCHAFTEN

  摘要：

  公开号：

  EP1216225B1

文献信息

• NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES
  申请人：Alonso-Alija Cristina

  公开号：US20100317854A1

  公开（公告）日：2010-12-16

  The invention relates to compounds of formulae (II), (IV), and (VI) as shown below, wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, and methods for using them in the synthesis of compounds for treatment of cardiovascular disorders and fibrotic disorders are also disclosed.

  本发明涉及以下式子的化合物（II），（IV）和（VI），其中各个变量组在规范和要求中定义。还公开了制备这些材料的过程，以及在合成用于治疗心血管疾病和纤维化疾病的化合物的方法。
• METHOD OF IDENTIFYING A SUBGROUP OF PATIENTS SUFFERING FROM DCSSC WHICH BENEFITS FROM A TREATMENT WITH SGC STIMULATORS AND SGC ACTIVATORS IN A HIGHER DEGREE THAN A CONTROL GROUP
  申请人：Adverio Pharma GmbH

  公开号：EP3574905A1

  公开（公告）日：2019-12-04

  The present invention relates to a method of identifying a subgroup of patients suffering from diffuse cutaneous systemic sclerosis (dcSSc) which subgroup of patients benefits from a treatment with at least one sGC stimulator and/or sGC activator in a higher degree than patients not belonging to this subgroup.

  本发明涉及一种确定弥漫性皮肤系统性硬化症（dcSSc）患者亚群的方法，该亚群患者从至少一种sGC刺激剂和/或sGC激活剂的治疗中获益的程度高于不属于该亚群的患者。
• Method for creating a renal injury model to screen molecules for the treatment of renal injury
  申请人：BAYER AKTIENGESELLSCHAFT

  公开号：US11439713B2

  公开（公告）日：2022-09-13

  The present invention is related to short-term renal injury models and methods for creating these models. The models and methods can be used for identifying, testing or characterizing candidate molecules with respect to their suitability to treat renal injury. The methods comprise a step of inducing, in a test subject, renal injury by administering subcutaneously a bolus of a renal injury inducer, in a dosage sufficiently high to induce renal injury. Different types of readout for renal injury are provided such as albumin creatinine ratio (ACR) determined in a urine sample taken from the subject, or the development of transcutaneous fluorescence after injection of a fluorescent molecule. Based on the readout the degree of renal injury and/or alteration of GFR can be determined.

  本发明涉及短期肾损伤模型和创建这些模型的方法。这些模型和方法可用于鉴定、测试或表征候选分子治疗肾损伤的适宜性。这些方法包括一个步骤，即通过皮下注射肾损伤诱导剂，以足够高的剂量诱发受试者的肾损伤。提供了不同类型的肾损伤读数，如从受试者尿样中测定的白蛋白肌酐比值（ACR），或注射荧光分子后经皮荧光的发展。根据读数可以确定肾损伤程度和/或肾小球滤过率的变化。
• METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION
  申请人：Mayo Foundation for Medical Education and Research

  公开号：EP3952992A1

  公开（公告）日：2022-02-16
• THE USE OF SGC ACTIVATORS AND SGC STIMULATORS FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
  申请人：Bayer Aktiengesellschaft

  公开号：US20210052528A1

  公开（公告）日：2021-02-25

  The present invention relates to sGC activators and sGC stimulators for use in the treatment of cognitive impairment in a mammal in need of such treatment, in particular for use in the treatment of vascular dementia.